a 66-year-old woman
Membranous nephropathy with impure nephrotic syndrome and positive anti-PLA2R antibodies, alongside a pulmonary adenocarcinoma
Her nephrotic syndrome did not go away after the lung cancer was surgically treated and the tumor went into remission. She reached remission only after she was given immunosuppressive therapy.
A 66-year-old woman with membranous nephropathy and positive anti-PLA2R antibodies got better only after immune-suppressing treatment, not after her lung cancer was removed, suggesting her kidney disease was the primary form all along.
- She had membranous nephropathy confirmed by a kidney biopsy, along with impure nephrotic syndrome.
- Her blood tested positive for anti-PLA2R antibodies, which usually point to the primary (kidney-driven) form of the disease.
- Doctors first blamed her lung cancer and called it a secondary form, but her kidney problem did not go away after surgery removed the tumor.
- Remission of the nephrotic syndrome came only after she started immunosuppressive therapy.
- The lesson the authors draw is that when anti-PLA2R is positive and the kidney does not recover, doctors should reconsider the primary form even when another cause looks obvious.
Why it might work
Membranous nephropathy damages the tiny filters in the kidney. In the primary form, the body makes antibodies against a protein on kidney cells called PLA2R, and these antibodies drive the damage. Because this woman kept testing positive for anti-PLA2R and stayed sick after her tumor was gone, the paper frames her disease as this antibody-driven primary form rather than something the cancer caused. Immunosuppressive therapy calms the immune system that makes those antibodies, which is why the authors say her remission only came after that treatment.
The honest limits
- This is a single case report (n=1), so it cannot tell you how often this happens or whether the same approach would help anyone else.
- The abstract gives no lab numbers, such as protein levels, antibody titers, or kidney function (eGFR), so there is no way to measure how much she improved.
- It does not name which immunosuppressive drugs were used, at what dose, or for how long.
- The abstract discloses no follow-up length and no conflicts of interest, so long-term outcomes and funding are unknown.
- Have I been tested for anti-PLA2R antibodies, and what did the result mean for whether my membranous nephropathy is primary or secondary?
- If I have another condition that could explain my kidney disease, how will we decide whether it is truly the cause?
- If my nephrotic syndrome does not improve after treating the other condition, would immunosuppressive therapy be an option for me, and what are its risks?